Expert Opinion on Investigational Drugs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Drugs in preclinical and early clinical development for the treatment of chagas disease: the current status
Expert Opin Investig Drugs. 2024 Apr 30. doi: 10.1080/13543784.2024.2349289. Online ahead of print.ABSTRACTINTRODUCTION: Chagas disease is spreading faster than expected in different countries and little progress has been reported in the discovery of new drugs to combat Trypanosoma cruzi infection in humans. Recent clinical trials have ended with small hope. The pathophysiology of this neglected disease and the genetic diversity of parasites are exceptionally complex. The only two drugs available to treat patients are far from being safe, and their efficacy in the chronic phase is still unsatisfactory.AREAS COVERED: This r...
Source: Expert Opinion on Investigational Drugs - April 30, 2024 Category: Drugs & Pharmacology Authors: Fernanda Karoline Vieira da Silva Torchelsen Ana Lia Mazzeti Vanessa Carla Furtado Mosqueira Source Type: research

Novel investigational drugs for alopecia areata and future perspectives
Expert Opin Investig Drugs. 2024 Apr 29. doi: 10.1080/13543784.2024.2348062. Online ahead of print.ABSTRACTINTRODUCTION: Alopecia areata (AA) is an immune-mediated disease that causes non-scarring hair loss. While acute, solitary patches often spontaneously remit, developing secondary patches or failure of the disease to resolve within 6-12 months predicts a poor prognosis, with an increased risk of alopecia totalis or universalis. Chronic AA increases the risk of depression and suicidality and reduces quality of life. Treatment options for chronic or acute diffuse AA were previously limited to corticosteroids and traditio...
Source: Expert Opinion on Investigational Drugs - April 29, 2024 Category: Drugs & Pharmacology Authors: Ivana Chim Ragini Ghiya Rodney D Sinclair Samantha Eisman Source Type: research

Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study
Expert Opin Investig Drugs. 2024 Apr 27. doi: 10.1080/13543784.2024.2348068. Online ahead of print.ABSTRACTINTRODUCTION: FAK, a nonreceptor cytoplasmic tyrosine kinase, plays a crucial role in tumor metastasis, drug resistance, tumor stem cell maintenance, and regulation of the tumor microenvironment. FAK has emerged as a promising target for tumor therapy based on both preclinical and clinical data.AREAS COVERED: This paper aims to summarize the molecular mechanisms underlying FAK's involvement in tumorigenesis and progression. Encouraging results have emerged from ongoing clinical trials of FAK inhibitors. Additionally, ...
Source: Expert Opinion on Investigational Drugs - April 27, 2024 Category: Drugs & Pharmacology Authors: Jiaming Gao Jingwen Cheng Wanyu Xie Ping Zhang Xuebin Liu Zaiqi Wang Baoyuan Zhang Source Type: research

Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis
Expert Opin Investig Drugs. 2024 Apr 27. doi: 10.1080/13543784.2024.2348743. Online ahead of print.ABSTRACTINTRODUCTION: Up to 40% of Primary biliary cholangitis (PBC) patients have a suboptimal response to Ursodeoxycholic acid (UDCA). Close to half of such patients show a remarkable improvement when additionally treated with Obeticholic acid (OCA) but have a dose-dependent increase of pruritus. This relative success of OCA, a first-in-class Farnesoid receptor (FXR) agonist, has positioned FXR as an attractive target for drug development. Novel candidates have since emerged, providing hope for this subgroup of patients who...
Source: Expert Opinion on Investigational Drugs - April 27, 2024 Category: Drugs & Pharmacology Authors: Prithvi Reddy Akepati Eric M Gochanour Source Type: research

Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind phase I study in healthy subjects
CONCLUSION: SHEN26 demonstrated satisfactory safety and tolerability in healthy subjects, which supports the continued study of SHEN26 against SARS-CoV-2.TRIAL REGISTRATION: The trial is registered in ClinicalTrials.gov (CT. gov identifier: NCT05504746).PMID:38662639 | DOI:10.1080/13543784.2024.2347302 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - April 25, 2024 Category: Drugs & Pharmacology Authors: Cheng Sun Hao Liu Ziwei Ouyang Jie Ding Qin Zhang Hongjie Ma Dandan Xu Qian Zhang Renpeng Zhou Mingming Yang Wei Hu Source Type: research

Interleukin antagonists for atopic dermatitis: a new era of therapy
Expert Opin Investig Drugs. 2024 Apr 24. doi: 10.1080/13543784.2024.2347294. Online ahead of print.ABSTRACTINTRODUCTION: Over the last decade, increasing understanding of the immunopathogenesis of atopic dermatitis (AD) enabled the recognition of multiple therapeutic targets and subsequently the development of novel, highly effective systemic treatments, including interleukin (IL)-antagonists. To date, the IL-4Ra-inhibitor dupilumab, and the IL-13 inhibitor tralokinumab, have gained regulatory approval in Europe for the treatment of moderate-to-severe AD, while more than 70 new therapeutics are currently in development.ARE...
Source: Expert Opinion on Investigational Drugs - April 24, 2024 Category: Drugs & Pharmacology Authors: Aikaterini Tsiogka Eleni Paschou Dimitra Koumaki Efstratios Vakirlis Stamatios Gregoriou Source Type: research

Investigational drugs for the Treatment of Acromegaly: new agents to transform therapy
Expert Opin Investig Drugs. 2024 Apr 23. doi: 10.1080/13543784.2024.2343056. Online ahead of print.ABSTRACTINTRODUCTION: Disease control is essential to decrease morbidity burden and mortality in acromegaly patients. In the last decades, the availability of new drugs increased the rate of disease control. However, up to 55% of patients remain uncontrolled despite available treatment strategies in real-world data. The reasons for this finding may include poor adherence, inadequate tolerability, therapeutic inertia, and high costs. Since acromegaly is a chronic disease and medical therapy is usually life-long, patient's adhe...
Source: Expert Opinion on Investigational Drugs - April 23, 2024 Category: Drugs & Pharmacology Authors: Rosa Pirchio Renata S Auriemma Alice Vergura Rosario Pivonello Annamaria Colao Source Type: research

TARGETING DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME: HOPES or HYPES?
Expert Opin Investig Drugs. 2024 Apr 23. doi: 10.1080/13543784.2024.2347296. Online ahead of print.NO ABSTRACTPMID:38653572 | DOI:10.1080/13543784.2024.2347296 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - April 23, 2024 Category: Drugs & Pharmacology Authors: Gabrio Bassotti Source Type: research

Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights
Expert Opin Investig Drugs. 2024 Apr 21:1-16. doi: 10.1080/13543784.2024.2342327. Online ahead of print.ABSTRACTINTRODUCTION: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited kidney condition caused by a single-gene mutation. It leads patients to kidney failure in more than 50% of cases by the age of 60, and, given the dominant inheritance, this disease is present in the family history in more than 90% of cases.AREAS COVERED: This review aims to analyze the set of preclinical and early-phase studies to provide a general view of the current progress on ADPKD therapeutic options. Articles fro...
Source: Expert Opinion on Investigational Drugs - April 15, 2024 Category: Drugs & Pharmacology Authors: Irene Capelli Sarah Lerario Francesca Ciurli Gian Marco Berti Valeria Aiello Michele Provenzano Gaetano La Manna Source Type: research